Table 3 Survival-related characteristics in type II PSOCs underwent SCR
Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
TTP (OR 95%CI) | OS (OR 95%CI) | TTP (OR 95%CI) | OS (OR 95%CI) | |
FIGO stage | ||||
 I-II | 1.00(reference) | 1.00(reference) | 1.00(reference) | 1.00(reference) |
 III-IV | 3.55 (1.89–10.05) | 4.18 (2.42–11.27) | 2.13 (0.93–4.28) | 3.24 (0.83–4.28) |
 Ascites | 1.85 (1.35–2.54) | 1.99 (1.38–2.33) | 1.54 (1.25–2.06) | 1.85 (0.83–2.25) |
 Optimal initial CRS | 6.33 (2.26–16.08) | 6.20 (3.53–15.06) | 5.08 (2.45–15.25) | 6.12 (3.44–14.67) |
 Optimal SCR | 4.81 (1.98–13.21) | 5.95 (3.45–17.26) | 4.68 (1.85–13.48) | 6.28 (4.20–16.60) |
 NAC | 1.12 (0.96–1.49) | 1.25 (0.77–2.27) | 1.19 (0.94–1.47) | 1.25 (0.82–2.21) |
 SNAC | 1.10 (0.73–1.28) | 1.29 (0.80–2.02) | 1.05 (0.87–1.35) | 1.21 (0.88–1.97) |
 PFI | 1.08 (1.00–1.15) | 1.12 (1.08–1.25) | 1.08 (1.00–1.17) | 1.12 (1.07–1.26) |
 Nadir CA-125 | 1.01 (1.00–1.03) | 1.02 (1.00–1.05) | 1.02 (1.00–1.02) | 1.03 (1.00–1.05) |